Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

被引:219
作者
Demento, Stacey L. [1 ]
Eisenbarth, Stephanie C. [2 ,7 ]
Foellmer, Harald G. [3 ]
Platt, Craig [4 ]
Caplan, Michael J. [5 ]
Saltzman, W. Mark [1 ]
Mellman, Ira [4 ]
Ledizet, Michel [6 ]
Fikrig, Erol [3 ,8 ]
Flavell, Richard A. [2 ,8 ]
Fahmy, Tarek M. [1 ]
机构
[1] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA
[2] Yale Univ, Dept Immunobiol, New Haven, CT 06511 USA
[3] Yale Univ, Dept Internal Med, Infect Dis Sect, New Haven, CT 06511 USA
[4] Yale Univ, Dept Cell Biol, New Haven, CT 06511 USA
[5] Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06511 USA
[6] L2 Diagnost LLC, New Haven, CT 06511 USA
[7] Yale Univ, Dept Lab Med, New Haven, CT 06511 USA
[8] Howard Hughes Med Inst, Chevy Chase, MD USA
关键词
PLGA; Inflammasome; West Nile virus; Nanoparticles; WEST-NILE-VIRUS; ANTIGEN-PRESENTING CELLS; MONOPHOSPHORYL-LIPID-A; TOLL-LIKE RECEPTORS; MHC CLASS-I; NALP3; INFLAMMASOME; EXOGENOUS ANTIGENS; ALUMINUM ADJUVANTS; DENDRITIC CELLS; IMMUNE-RESPONSE;
D O I
10.1016/j.vaccine.2009.03.034
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Innate immune system activation is a critical step in the initiation of an effective adaptive immune response; therefore, activation of a class of innate pathogen receptors called pattern recognition receptors (PRR) is a central feature of many adjuvant systems. It has recently been shown that one member of an intracellular PRR, the NLRP3 inflammasome, is activated by a number of classical adjuvants including aluminum hydroxide and saponins [Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453(June (7198)):1122-6; Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181 (July (1)):17-21]. Inflammasome activation in vitro requires signaling of both the Toll-like receptor (TLR) and NLRP3 in antigen-presenting cells. Here we present a class of nanomaterials endowed with these two signals for rapid optimization of vaccine design. We constructed this system using a simple approach that incorporates lipopolysaccharides (LPS) onto the surface of nanoparticles constructed from a biocompatible polyester, poly(lactic-co-glycolic acid) (PLGA), loaded with antigen. We demonstrate that LPS-modified particles are preferentially internalized by dendritic cells compared to uncoated nanoparticles and the system, when administered to mice, elicits potent humoral and cellular immunity against a model antigen, ovalbumin. Wild-type macrophages pulsed with LPS-modified nanoparticles resulted in production of the proinflammatory cytokine IL-1 beta consistent with inflammasome activation. In comparison, NLRP3-deficient and caspase-1-deficient macrophages showed negligible production of IL-1 beta. Furthermore, when endocytosis and lysosomal destabilization were inhibited, inflammasome activity was diminished, supporting the notion that nanoparticles rupture lysosomal compartments and behave as 'danger signals' [Hornung V, Bauernfeind F, Halle A, Samstad EO. Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9(August (8)):847-561]. The generality of this vaccination approach is tested by encapsulation of a recombinant West Nile envelope protein and demonstrated by protection against a murine model of West Nile encephalitis. The design of such an antigen delivery mechanism with the ability to stimulate two potent innate immune pathways represents a potent new approach to simultaneous antigen and adjuvant delivery. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3013 / 3021
页数:9
相关论文
共 38 条
[21]   Recent advances in the discovery and delivery of vaccine adjuvants [J].
O'Hagan, DT ;
Valiante, NM .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :727-735
[22]   Targeting the innate immune response with improved vaccine adjuvants [J].
Pashine, A ;
Valiante, NM ;
Ulmer, JB .
NATURE MEDICINE, 2005, 11 (04) :S63-S68
[23]   Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants [J].
Peter, K ;
Men, Y ;
Pantaleo, G ;
Gander, B ;
Corradin, G .
VACCINE, 2001, 19 (30) :4121-4129
[24]   TOXICITY AND IMMUNOGENICITY OF NEISSERIA-MENINGITIDIS LIPOPOLYSACCHARIDE INCORPORATED INTO LIPOSOMES [J].
PETROV, AB ;
SEMENOV, BF ;
VARTANYAN, YP ;
ZAKIROV, MM ;
TORCHILIN, VP ;
TRUBETSKOY, VS ;
KOSHKINA, NV ;
LVOV, VL ;
VERNER, IK ;
LOPYREV, IV ;
DMITRIEV, BA .
INFECTION AND IMMUNITY, 1992, 60 (09) :3897-3903
[25]   Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis [J].
Purtha, Whitney E. ;
Myers, Nancy ;
Mitaksov, Vesselin ;
Sitati, Elizabeth ;
Connolly, Janet ;
Fremont, Daved H. ;
Hansen, Ted H. ;
Diamond, Michael S. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (07) :1845-1854
[26]   Lipopolysaccharide and monophosphoryl lipid a differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages [J].
Salkowski, CA ;
Detore, GR ;
Vogel, SN .
INFECTION AND IMMUNITY, 1997, 65 (08) :3239-3247
[27]   European union regulatory developments for new vaccine adjuvants and delivery systems [J].
Sesardic, D ;
Dobbelaer, R .
VACCINE, 2004, 22 (19) :2452-2456
[28]  
Shen ZH, 1997, J IMMUNOL, V158, P2723
[29]   Role of CD8+ T cells in control of West Nile virus infection [J].
Shrestha, B ;
Diamond, MS .
JOURNAL OF VIROLOGY, 2004, 78 (15) :8312-8321
[30]   Recent advances in vaccine adjuvants [J].
Singh, M ;
O'Hagan, DT .
PHARMACEUTICAL RESEARCH, 2002, 19 (06) :715-728